Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems-Reference-Cited by-同舟云学术

Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems

Published:2018-06 Issue:6 Volume:28 Page:533-542
ISSN:0939-4753
Container-title:Nutrition, Metabolism and Cardiovascular Diseases
language:en
Short-container-title:Nutrition, Metabolism and Cardiovascular Diseases

Author:

Raschi E.^ORCID,Poluzzi E.^ORCID,Salvo F.,Pariente A.,De Ponti F.,Marchesini G.^ORCID,Moretti U.

Funder

Institutional funds of the University of Bologna

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Reference50 articles.

1. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database;Perlman;Nutr Metabol Cardiovasc Dis,2017

2. Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems;Raschi;Nutr Metabol Cardiovasc Dis,2017

3. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System;Fadini;Diabetologia,2017

4. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system;Fadini;Lancet Diabetes Endocrinol,2017

5. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database;Ado Moumouni;Fundam Clin Pharmacol,2017

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality;JAMA Network Open;2024-08-20

2. Sodium-glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study;Journal of Cardiovascular Medicine;2024-06-27

3. Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis;BioDrugs;2024-06-14

4. Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database;Scientific Reports;2024-05-31

5. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis;Expert Review of Cardiovascular Therapy;2024-05-12